Mochida Pharmaceutical Company
CompanyJapan
Mochida Pharmaceutical Company develops one asset, approved (icosapent ethyl in Angina, Unstable). Mostly small molecule acting on lipid and ceramide metabolism and inflammation; based in Japan.
- 1
- Asset
- Furthest stage
- Approved
- 1
- Trial
- 0
- Signals
Pipeline
1Ethyl ester of eicosapentaenoic acid that lowers triglyceride levels
Approved, Small molecule, Lipid and ceramide metabolism, Inflammation, Angina, Unstable, cardiovascular disease
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials2
- Signals1
- Similar companies6
Papers
Enhanced Renal Protective Effects of Tirzepatide in T2D People
ADA Scientific Sessions 2025 abstract, 13 Jun 2025